Get started
Author

Maria Frances Coakley

Observed names: M. Coakley, M.F. Coakley, Maria Coakley, Maria F Coakley, Maria F. Coakley
Observed institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Breast Cancer Now, Cork University Hospital, Royal Marsden Hospital, Mayo Clinic in Arizona
ORCID: 0000-0003-2658-7789
Observed ORCID: 0000-0003-2658-7789
OpenAlex ID: A5081483450
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
2022 · N.C. Turner, C. Swift, et al. · Annals of Oncology · 210
PDF
Survival following allogeneic transplant in patients with myelofibrosis
2020 · Krisstina Gowin, Karen Ballen, et al. · Blood Advances · 99
PDF
Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors
2019 · Maria Coakley, Isaac Garcia-Murillas, et al. · Clinical Cancer Research · 69
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
2023 · Maria Coakley, Guillermo Villacampa, et al. · Clinical Cancer Research · 51
PDF
Association of post-operative ctDNA detection with outcomes of patients with early breast cancers
2024 · R. Cutts, L. Ulrich, et al. · ESMO Open · 31
PDF
Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis
2016 · K. Gowin, M. Coakley, et al. · Haematologica · 24
Extramedullary Cardiac Multiple Myeloma—A Case Report and Contemporary Review of the Literature
2016 · Maria Coakley, Beeletsega Yeneneh, et al. · Clinical Lymphoma Myeloma & Leukemia · 18
Abstract GS3-06: Primary results of the cTRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer
2022 · Nicholas Turner, Claire Swift, et al. · Cancer Research · 15
Abstract 536: Molecular residual disease detection in early stage breast cancer with a personalized sequencing approach
2021 · Rosalind J. Cutts, Maria Coakley, et al. · Cancer Research · 9
Management of lung cancer
2020 · Maria Coakley, Sanjay Popat · Medicine · 8
Impact of timing of adjuvant chemotherapy for early breast cancer: the Royal Marsden Hospital experience
2021 · Alicia F. C. Okines, Emma Kipps, et al. · British Journal of Cancer · 6
Circulating tumour DNA assays in focus: highlights from ASCO 2025 for clinicians
2025 · Maria Frances Coakley, Javier Pascual, et al. · BJC Reports · 4
PDF
Abstract PD5-03: PD5-03 Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial
2023 · Maria Coakley, Prithika Sritharan, et al. · Cancer Research · 4
Abstract P2-01-10: Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery
2022 · Isaac Garcia-Murillas, Rosalind J Cutts, et al. · Cancer Research · 2
Comparison of the Utility of Transesophageal Echocardiography in Patients With Acute Ischemic Stroke and Transient Ischemic Attack Stratified by Age Group (<60, 60 to 80, ≥80 Years)
2018 · Ryan C. Van Woerkom, Steven J. Lester, et al. · The American Journal of Cardiology · 2
BRCA1/2 germline testing in non-mucinous epithelial ovarian carcinoma: changing international practice and implications for service provision
2016 · Maria Coakley, Vicki Cleary, et al. · European Journal of Human Genetics · 2
PDF
Prevention of Everolimus-related Stomatitis: a Retrospective and Prospective Study
2019 · M. Coakley, I. Leslie, et al. · Clinical Oncology · 1
Impact of delayed adjuvant chemotherapy: The Royal Marsden Hospital (RMH) experience
2019 · A.F.C. Okines, E. Kipps, et al. · Annals of Oncology · 1
PDF
Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer
2026 · Niamh Cunningham, Rosalind J. Cutts, et al. · JAMA Oncology
2308P The triple planetary crisis: Implications for Ireland’s next national cancer strategy
2025 · H.K. Carroll, C. Forrest, et al. · Annals of Oncology
Abstract 3781: Tracking triple negative breast cancer (TNBC) evolution in the molecular residual disease (MRD) setting in the c-TRAK TN clinical trial
2024 · Maria Coakley, Rosalind J. Cutts, et al. · Cancer Research
Supplementary Table S5 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
2024 · Maria Coakley, Guillermo Villacampa, et al.
Supplementary Table S5 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
2024 · Maria Coakley, Guillermo Villacampa, et al.
Supplementary Figure S1 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
2024 · Maria Coakley, Guillermo Villacampa, et al.
Supplementary Table S4 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
2024 · Maria Coakley, Guillermo Villacampa, et al.
Works count: 45
Citation count: 554
H-index: 9
I10-index: 8
Year
Topic
Type